Reduced Intensity Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorders is Associated with Preserved Survival Outcomes: A Twenty-Year Single-Institutional Experience

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis reports on survival outcomes in patients with PCNS-PTLD, suggesting rituximab may improve treatment safety.

The median overall survival for patients with PCNS-PTLD was 71.2 months, indicating preserved outcomes despite shifts in therapy.
Univariate analysis revealed that lower lactate dehydrogenase levels were significantly associated with improved overall and progression-free survival.
A significant treatment shift occurred from high-dose methotrexate and radiation to first-line rituximab in the latest cohort of patients.
The findings highlight the potential benefits of reduced toxicity therapies and the need for further research in optimizing treatment for PCNS-PTLD.

Uyemura et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark